Literature DB >> 23151854

Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction.

Ko-Fan Wang1, Po-Hsun Huang, Chia-Hung Chiang, Chien-Yi Hsu, Hsin-Bang Leu, Jaw-Wen Chen, Shing-Jong Lin.   

Abstract

OBJECTIVES: This study aims to determine whether plasma levels of matrix metalloproteinases (MMPs) and inflammatory markers can predict the long-term prognosis of coronary revascularization in patients after acute myocardial infarction (AMI).
BACKGROUND: MMPs have been implicated in the development of atherosclerosis and plaque rupture in acute coronary syndrome.
METHODS: Ninety-six consecutive patients (63±11 years) diagnosed with myocardial infarction were enrolled. All patients were followed up for 43±12 months. Plasma levels of MMP-2 and MMP-9 were determined from blood samples collected immediately after hospitalization. Coronary revascularization was defined as having received a percutaneous coronary intervention or a coronary artery bypass graft surgery.
RESULTS: A total of 29 patients (30%) had undergone coronary revascularization during the follow-up period, including 27 percutaneous coronary intervention and two coronary artery bypass graft surgery. The baseline characteristics were similar between groups with or without revascularization. Patients with coronary revascularization had significantly higher MMP-9 levels (P=0.048), but not MMP-2 levels. In addition, a positive correlation was found between circulating MMP-9 level and total cholesterol (r=0.250, P=0.016) and low-density lipoprotein-cholesterol (r=0.284, P=0.009). All patients were divided into a high-MMP-9 group (highest tertile≥1.10 ng/ml) and a low-MMP-9 group (<1.10 ng/ml). The incidence of coronary revascularization was significantly increased in the high-MMP-9 group (P=0.034). In a multivariate Cox regression analysis that included MMP-9 and classical risk factors, the MMP-9 level was an independent predictor of coronary revascularization in patients after AMI (hazard ratio, 2.72; 95% confidence interval, 1.24-5.98; P=0.026).
CONCLUSION: Increased plasma levels of MMP-9 but not MMP-2 or inflammatory markers predict future coronary revascularization, and a significant association was observed with MMP-9 and low-density lipoprotein-cholesterol. These findings suggest a pivotal role of MMP-9 in atherothrombosis in AMI patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23151854     DOI: 10.1097/MCA.0b013e32835aab4a

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  12 in total

1.  Novel Biomarkers: Utility in Patients with Acute Chest Pain and Relationship to Coronary Artery Disease on Coronary CT Angiography.

Authors:  Adefolakemi Babatunde; Asim Rizvi; Quynh A Truong
Journal:  Curr Cardiovasc Imaging Rep       Date:  2014-07

2.  Investigation of MMP-2 and MMP-9 activities in canine sera with dilated cardiomyopathy.

Authors:  S Chegeni; Z Khaki; D Shirani; A Vajhi; M Taheri; Y Tamrchi; A Rostami
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

3.  Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling.

Authors:  Brendan P Purcell; Shayne C Barlow; Paige E Perreault; Lisa Freeburg; Heather Doviak; Julia Jacobs; Abigail Hoenes; Kia N Zellars; Aarif Y Khakoo; TaeWeon Lee; Jason A Burdick; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-06       Impact factor: 4.733

4.  Apigenin attenuates acute myocardial infarction of rats via the inhibitions of matrix metalloprotease-9 and inflammatory reactions.

Authors:  Hong Du; Jie Hao; Fan Liu; Jingchao Lu; Xiuchun Yang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

5.  Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.

Authors:  Janine Koepke; Marc Dresel; Severin Schmid; Timm Greulich; Björn Beutel; Bernd Schmeck; Claus Franz Vogelmeier; Sabina Janciauskiene; Andreas Rembert Koczulla
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

6.  Matrix Metalloproteinase-9 Production following Cardiopulmonary Bypass Was Not Associated with Pulmonary Dysfunction after Cardiac Surgery.

Authors:  Tso-Chou Lin; Feng-Yen Lin; Yi-Wen Lin; Che-Hao Hsu; Go-Shine Huang; Zhi-Fu Wu; Yi-Ting Tsai; Chih-Yuan Lin; Chi-Yuan Li; Chien-Sung Tsai
Journal:  Mediators Inflamm       Date:  2015-07-27       Impact factor: 4.711

7.  Blood Biomarkers of Chronic Inflammation in Gulf War Illness.

Authors:  Gerhard J Johnson; Billie C S Slater; Linda A Leis; Thomas S Rector; Ronald R Bach
Journal:  PLoS One       Date:  2016-06-28       Impact factor: 3.240

8.  Usefulness of plasma matrix metalloproteinase-9 levels in prediction of in-hospital mortality in patients who received emergent percutaneous coronary artery intervention following myocardial infarction.

Authors:  Jia-Jun Zhu; Qian Zhao; Hui-Juan Qu; Xiao-Mei Li; Qing-Jie Chen; Fen Liu; Bang-Dang Chen; Yi-Ning Yang
Journal:  Oncotarget       Date:  2017-11-11

9.  Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions.

Authors:  Jéssica Cavalcante Dos Santos; Marina Sampaio Cruz; Raul Hernandes Bortolin; Katiene Macêdo de Oliveira; Jéssica Nayara Góes de Araújo; Victor Hugo Rezende Duarte; Ananília Medeiros Gomes da Silva; Isabelle Cristina Clemente Dos Santos; Juliana Marinho de Oliveira Dantas; Maria Sanali Moura de Oliveira Paiva; Adriana Augusto Rezende; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata; André Ducati Luchessi; Vivian Nogueira Silbiger
Journal:  Clinics (Sao Paulo)       Date:  2018-05-28       Impact factor: 2.365

Review 10.  Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review.

Authors:  Andreas Kousios; Panayiotis Kouis; Andrie G Panayiotou
Journal:  Int J Nephrol       Date:  2016-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.